Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.
The primary study objective was to evaluate the prognostic value of post-therapeutic SPECT by RECIP 1.0 for overall survival.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback